Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

OPTN: A Possible Genetic Cause of Both CBS and ALS
Movement Disorders
P9 - Poster Session 9 (5:30 PM-6:30 PM)
5-013

CBS is defined by atypical parkinsonism and specific examination findings indicating cortical dysfunction. In contrast, corticobasal degeneration (CBD) is a pathological entity and is the principal pathology underlying CBS. CBD and frontotemporal dementia (FTD) often involve tau deposition, but in different topographical distributions, and also in different molecular forms. Many cases of CBD and FTD may, in addition, overlap clinically. By comparison, there is significantly less clinical overlap between ALS and the pathologies that cause CBS. Here we report a case of CBS linked to a mutation in the OPTN gene. This individual has several close relatives diagnosed with familial ALS who also have been found to carry the same OPTN mutation.

To report a patient with a mutation typically associated with familial amyotrophic lateral sclerosis (ALS), but instead presenting with the corticobasal syndrome (CBS) phenotype.

NA

We report a 49-year-old man with 6 months of involuntary movements of the right upper extremity, followed by gait unsteadiness and memory changes. Family history was notable for two siblings with ALS linked to a mutation in the OPTN gene. On exam, we noted right hemidystonia, as well as bradykinesia and brisk reflexes in the right arm. There was gait ataxia, as well as right-sided astereognosis, agraphesthesia, tactile extinction, and ideomotor apraxia. No ocular abnormalities, orthostasis, or other upper-motor neuron features were seen. MRI showed left peri-Rolandic fissure atrophy. Gene testing revealed homozygosity for a loss of function splice-site mutation in the OPTN gene.

This case illustrates differential effects of the same gene mutation in different family members. It is interesting that the pathology causing CBS in this patient shares the same mutation with an inherited form of ALS. The heterogeneity of OPTN phenotypes may be a consequence of the same neuropathology, but with differential topographical distribution in the nervous system.

Authors/Disclosures
Matthew Feldman, MD (Movement Disorders Fellowship - University of Miami)
PRESENTER
Dr. Feldman has nothing to disclose.
Michael G. Benatar, MBChB, DPhil, FAAN (University of Miami) Dr. Benatar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Benatar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arrowhead. Dr. Benatar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Annexon. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UniQure. Dr. Benatar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cartesian. Dr. Benatar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Benatar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Benatar has received intellectual property interests from a discovery or technology relating to health care.
Efrat Saraf Lavi, MD Dr. Saraf Lavi has nothing to disclose.
Kumarie Latchman, DO (University of Miami Miller School of Medicine Department of Genetics) Dr. Latchman has nothing to disclose.
Carlos Singer, MD (University of Miami) Dr. Singer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amneal. Dr. Singer has received personal compensation in the range of $10,000-$49,999 for serving as a Video Panel with CNS Ratings LLC. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Course Organiztion with Omniprex Scientific Medical Eduaction. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with Health Monitor Network. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Movement Disorders Society. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Workshop Moderator with International Neurotoxin Association Inc. Dr. Singer has received personal compensation in the range of $500-$4,999 for serving as a Lecturer with CME Outfitteres LLC.